A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer

Background Improvements in knowledge of molecular mechanisms in cancer are the basis for new studies combining chemotherapy with targeted drugs. Inhibition of the epidermal growth factor receptor (EGFR) by erlotinib or cetuximab has limited or no activity, respectively, in pancreatic cancer. The cro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kordes, Sil, Richel, Dick J., Klümpen, Heinz-Josef, Weterman, Mariëtte J., Stevens, Arnoldus J. W. M., Wilmink, Johanna W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553409/
https://www.ncbi.nlm.nih.gov/pubmed/22367239
http://dx.doi.org/10.1007/s10637-012-9802-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553409/
https://www.ncbi.nlm.nih.gov/pubmed/22367239
http://dx.doi.org/10.1007/s10637-012-9802-1

Ejemplares similares